Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 5.96M P/E - EPS this Y - Ern Qtrly Grth -
Income -5.09M Forward P/E - EPS next Y - 50D Avg Chg -40.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -50.00%
Dividend N/A Price/Book 9.26 EPS next 5Y - 52W High Chg -88.00%
Recommedations - Quick Ratio 13.39 Shares Outstanding 2.25M 52W Low Chg 1.00%
Insider Own 23.47% ROA -64.47% Shares Float 1.98M Beta -0.32
Inst Own 5.08% ROE -111.07% Shares Shorted/Prior 19.57K/14.46K Price 3.23
Gross Margin - Profit Margin - Avg. Volume 126,453 Target Price -
Oper. Margin - Earnings Date May 8 Volume 61,155 Change -6.10%
About Lixte Biotechnology Holdings, I

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Lixte Biotechnology Holdings, I News
03/27/24 NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
03/21/24 LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
02/27/24 Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
02/26/24 LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
01/29/24 First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
11/13/23 LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
10/16/23 LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration
10/09/23 LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
09/26/23 LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
09/20/23 LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
07/20/23 LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
07/18/23 LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
07/17/23 Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
06/23/23 LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
06/07/23 LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
06/05/23 Owning 53% in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) means that insiders are heavily invested in the company's future
06/02/23 LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023
05/30/23 Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
04/24/23 LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
04/04/23 LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
LIXT Chatroom

User Image huntersmithllc Posted - 3 hours ago

$LIXT

User Image Easteregg Posted - 4 hours ago

$LIXT For those of you who missed it, here's the fraud report. You guys can read it over the weekend then decide what to do on Monday. Happy good Friday! https://whitediamondresearch.com/archive/lixte-biotechnology-publication-yesterday-is-the-same-one-published-over-a-year-ago/

User Image DeanCon96 Posted - 4 hours ago

$LIXT still strong 🫡

User Image PuceslinkyTwits Posted - 4 hours ago

$LIXT go green!!!!

User Image huntersmithllc Posted - 5 hours ago

$LIXT - Make them cover!!!

User Image GDS100 Posted - 6 hours ago

$LIXT crush the shorts

User Image 704Dame Posted - 6 hours ago

$LIXT 👍🏾shhh shhh

User Image huntersmithllc Posted - 7 hours ago

$LIXT - Make these fu🌴🌴 wads cover

User Image huntersmithllc Posted - 7 hours ago

$LIXT

User Image TadPederson Posted - 7 hours ago

$LIXT $OTRK Leading ,,analysts' thoughts,👇

User Image danew82 Posted - 8 hours ago

$LIXT This being shorted because some lame institute compiled some fake news so it will drop. Do your own research. Once this is known that its a fake report, this will jump. Just watch.

User Image huntersmithllc Posted - 8 hours ago

$LIXT - Shorts and fud showing up I see. Close to cover time.

User Image Klipse05 Posted - 8 hours ago

$LIXT these cocksuckers are ruthless.

User Image _www_larval_com_ Posted - 8 hours ago

$LIXT has dropped -7% lower to -9% (~571Kv) a moment ago, follow for more volatility.

User Image Easteregg Posted - 8 hours ago

$LIXT https://x.com/WhiteResearch/status/1773372860603433415?s=20

User Image WarrenPuffet240 Posted - 9 hours ago

$DHAI 👀👀 $IBIO $LIXT $GNS

User Image Tinoxwx Posted - 9 hours ago

$LIXT why does it move so much?

User Image Tinoxwx Posted - 9 hours ago

@ANTHONYMOMO thoughts on $LIXT ?

User Image RealBreakoutTrades Posted - 9 hours ago

$LIXT nice bull flag on the 5 minute chart

User Image Eyecandy1234 Posted - 9 hours ago

$IBIO $CZOO $LIXT $GDHG this guy is a fake bull!

User Image RealBreakoutTrades Posted - 9 hours ago

$LIXT i am still holding this i am also keeping an eye on $AVTX $XLO and $BDRX for a possible entry in the next couple of minutes

User Image Easteregg Posted - 10 hours ago

$LIXT SCAM! SKIMMY SCAM! SCAM SCAM!

User Image randompics Posted - 10 hours ago

$LIXT man they love shorting this.

User Image GDS100 Posted - 10 hours ago

$LIXT let’s go

User Image huntersmithllc Posted - 10 hours ago

$LIXT

User Image Bigmoney4me Posted - 11 hours ago

$LIXT thoughts on $BDRX ??

User Image Sabrinaharrington Posted - 11 hours ago

$LIXT Analyst price target for next week

User Image Klipse05 Posted - 11 hours ago

$LIXT some conniving MFS controlling this today and yesterday. Float is so small it can go either way.

User Image Easteregg Posted - 12 hours ago

$LIXT WALLUP THAT ASS! GET THIS PUNK BACK TO $2 TODAY!

User Image SwissCherry69 Posted - 12 hours ago

$LIXT Stay focus! Maybe green in few minutes. Yesterday news was huge!🔥🍋

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bernards Rene Director Director Oct 02 Buy 2.4 10,000 24,000 25,000 10/05/23
van der Baan Bastiaan Jeroen President and CEO President and CEO Oct 03 Buy 2.80 10,000 28,000 11,000 10/05/23
Bernards Rene Director Director Dec 15 Buy 0.51 15,000 7,650 150,000 12/16/22
FORMAN ERIC Vice President and C.. Vice President and COO Nov 17 Buy 0.56 21,059 11,793 98,142 11/21/22
Bernards Rene Director Director Nov 14 Buy 0.53 52,500 27,825 125,000 11/15/22